Bollard Laboratory

About the Lab

Our lab's research interests focus on cell therapy for viral and malignant diseases. Led by Catherine Bollard, M.D., M.B.Ch. B., we are running clinical trials assessing the safety of adoptively transferred, virus-specific T cells for the prevention and treatment of viral infection including after allogeneic stem cell and cord blood transplant, as well as for the treatment of virus-associated malignancies such as EBV and HIV.

Most recently, the team has focused on targeting multiple viruses including HHV6, BK virus, CMV, adenovirus, parainfluenza, norovirus and most recently the coronavirus SARS-Cov2. In addition, we are investigating the utility of this approach using genetically modified cell therapies (NK cells and T cells) for blood cancers and solid tumors. We also are evaluating the efficacy of tumor-specific T cells for patients with leukemia and lymphoma and pediatric solid tumors. Further, we are interested in novel strategies to target the cancer stem cell and to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols.